Correction to: Amphetamine extended-release oral suspension (Adzenys ER™) and orally disintegrating tablets (Adzenys XR-ODT®) in attention-deficit hyperactivity disorder: a profile of their use (Drugs &amp; Therapy Perspectives, (2018), 34, 9, (411-419), 10.1007/s40267-018-0539-6)

Correction to: Amphetamine extended-release oral suspension (Adzenys ER™) and orally disintegrating tablets (Adzenys XR-ODT®) in attention-deficit hyperactivity disorder: a profile of their use (Drugs & Therapy Perspectives, (2018), 34, 9, (411-419), 10.1007/s40267-018-0539-6)

Lyseng-Williamson, K.

drugs and therapy perspectives 2018 Vol. 34 pp. 596

200

lysengwilliamson2018correctiondrugs

DOI:

ID: 61322

Ref Key: lysengwilliamson2018correctiondrugs

Use this key to autocite in SciMatic or Thesis Manager

No Bibliography

Account:

NFT Contract Address:

0x95644003c57E6F55A65596E3D9Eac6813e3566dA

Article ID:

61322

Unique Identifier:

10.1007/s40267-018-0567-2

Network:

Scimatic Chain (ID: 481)

Authors

Abstract

Journal Name

Year

Title

4/5

Blockchain Upload Locked

Complete all 5 checklist items to tokenize your article

Gas fees required in SCI Coins

Coming soon

Reference Key: lastname+year+titlefirstword+journalfirstword

Article Type (Article, Book, Proceedings etc.)

Add a reference in a raw form. Our automatic system will correct it later.